연구성과로 돌아가기
2022 연구성과 (160 / 280)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| WoS | SCOPUS | Document Type | Document Title | Abstract | Authors | Affiliation | ResearcherID (WoS) | AuthorsID (SCOPUS) | Author Email(s) | Journal Name | JCR Abbreviation | ISSN | eISSN | Volume | Issue | WoS Edition | WoS Category | JCR Year | IF | JCR (%) | FWCI | FWCI Update Date | WoS Citation | SCOPUS Citation | Keywords (WoS) | KeywordsPlus (WoS) | Keywords (SCOPUS) | KeywordsPlus (SCOPUS) | Language | Publication Stage | Publication Year | Publication Date | DOI | JCR Link | DOI Link | WOS Link | SCOPUS Link |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ○ | Meeting Abstract | Lotus-inspired multifunctional antifouling janus nanofibrous membrane for prevention of postsurgical tissue adhesion | Jeon, Yu Ri; Jo, Yun Kee | Kyungpook Natl Univ, Daegu, South Korea | TISSUE ENGINEERING PART A | TISSUE ENG PT A | 1937-3341 | 1937-335X | 28 | SCIE | CELL & TISSUE ENGINEERING;CELL BIOLOGY;ENGINEERING, BIOMEDICAL;MATERIALS SCIENCE, BIOMATERIALS | 2022 | 4.1 | 42.2 | 0 | Antifouling barrier; Antibacterial effect; Janus nanofibrous membrane; Tissue adhesion; Anti-adhesion | English | 2022 | 2022-10-01 | 바로가기 | 바로가기 | ||||||||||||||||
| ○ | Meeting Abstract | Osteogenic Application Of Diabetic Dental Pulp Cells By Hyperglycemia-upregulation | Kim, M.; Eom, H.; Giannobile, W. V.; Park, C. | Kyungpook Natl Univ, Dent Biomat, Daegu, South Korea; Harvard Sch Dent Med, Boston, MA USA | TISSUE ENGINEERING PART A | TISSUE ENG PT A | 1937-3341 | 1937-335X | 28 | SCIE | CELL & TISSUE ENGINEERING;CELL BIOLOGY;ENGINEERING, BIOMEDICAL;MATERIALS SCIENCE, BIOMATERIALS | 2022 | 4.1 | 42.2 | 0 | English | 2022 | 2022-08-01 | 바로가기 | 바로가기 | |||||||||||||||||
| ○ | Meeting Abstract | Quantum dot-loaded biopolymer-based nanocomposite for skin infection treatment | Nam, In Ho; Jo, Yun Kee; Cha, Hyung Joon | Pohang Univ Sci & Technol, Pohang, South Korea; Kyungpook Natl Univ, Daegu, South Korea | Joon, Hyung/AAO-8422-2020 | TISSUE ENGINEERING PART A | TISSUE ENG PT A | 1937-3341 | 1937-335X | 28 | SCIE | CELL & TISSUE ENGINEERING;CELL BIOLOGY;ENGINEERING, BIOMEDICAL;MATERIALS SCIENCE, BIOMATERIALS | 2022 | 4.1 | 42.2 | 0 | Photodynamic therapy; Quantum dots; Multidrug-resistance bacteria; Antibiotics | English | 2022 | 2022-10-01 | 바로가기 | 바로가기 | |||||||||||||||
| ○ | Meeting Abstract | RENAL PROTECTIVE EFFECT OF BELUGA LENTIL PRETREATMENT FOR ISCHEMIA-REPERFUSION INJURY | Lee, EunHye; Chun, So Young; Kim, Bomi; Yoon, BoHyun; Jang, Byung Ik; Park, Dong Jin; Lee, Jun Nyung; Han, Man-Hoon; Kim, Bum Soo; Song, Phil Hyun; Lee, Dong Woo; Yoo, Eun Sang; Kwon, Tae Gyun; Ha, Yun-Sok | Kyungpook Natl Univ Hosp, Joint Inst Regenerat Med, Daegu, South Korea; Kyungpook Natl Univ Hosp, Biomed Res Inst, Daegu, South Korea; Yeungnam Univ, Coll Med, Dept Internal Med, Gyongsan, South Korea; Kyungpook Natl Univ, Sch Med, Dept Urol, Daegu, South Korea; Kyungpook Natl Univ, Sch Med, Dept Pathol, Daegu, South Korea; Yeungnam Univ, Coll Med, Dept Urol, Gyongsan, South Korea | Kim, Soo-Yeon/ADR-9663-2022; Lee, Dong/H-2427-2012; Kim, Young-Bo/AAR-8052-2021 | eun90hye@gmail.com; | TISSUE ENGINEERING PART A | TISSUE ENG PT A | 1937-3341 | 1937-335X | 28 | SCIE | CELL & TISSUE ENGINEERING;CELL BIOLOGY;ENGINEERING, BIOMEDICAL;MATERIALS SCIENCE, BIOMATERIALS | 2022 | 4.1 | 42.2 | 0 | Kidney; Ischemia; Renal protection | English | 2022 | 2022-04 | 바로가기 | 바로가기 | ||||||||||||||
| ○ | Meeting Abstract | Shear stress-driven exosome production and transcriptomic analysis in 3D cultured osteocytic cells | Park, Eui Kyun; Lee, Su Jeong; Lim, Jiwon | Kyungpook Natl Univ, Daegu, South Korea | Lee, Su-Jeong/AAH-8467-2021 | TISSUE ENGINEERING PART A | TISSUE ENG PT A | 1937-3341 | 1937-335X | 28 | SCIE | CELL & TISSUE ENGINEERING;CELL BIOLOGY;ENGINEERING, BIOMEDICAL;MATERIALS SCIENCE, BIOMATERIALS | 2022 | 4.1 | 42.2 | 0 | Exosome; Shear stress; Osteocyte | English | 2022 | 2022-10-01 | 바로가기 | 바로가기 | |||||||||||||||
| ○ | Meeting Abstract | The Anti-metastatic Effect Of Pdk4 Inhibition In Bladder Cancer Via Akt, Erk, And Jnk Signaling Pathway | Lee, E.; Yoon, B.; Jeon, M.; Chun, S.; Lee, J.; Chung, J.; Kim, B.; Kwon, T.; Ha, Y. | Kyungpook Natl Univ, Daegu, South Korea; Kyungpook Natl Univ Hosp, Daegu, South Korea | Ha, YooJin/JXN-9928-2024 | TISSUE ENGINEERING PART A | TISSUE ENG PT A | 1937-3341 | 1937-335X | 28 | SCIE | CELL & TISSUE ENGINEERING;CELL BIOLOGY;ENGINEERING, BIOMEDICAL;MATERIALS SCIENCE, BIOMATERIALS | 2022 | 4.1 | 42.2 | 0 | English | 2022 | 2022-08-01 | 바로가기 | 바로가기 | ||||||||||||||||
| ○ | Meeting Abstract | The anti-tumor effect and mechanism of PDK4 in bladder cancer | Lee, Eun Hye; Chun, So Young; Yoon, Bo Hyun; Jeon, Minji; Kim, Hyun Tae; Chung, Jae-Wook; Lee, Jun Nyung; Kwon, Tae Gyun; Kim, Bum Soo; Ha, Yun-Sok | Kyungpook Natl Univ, Daegu, South Korea; Kyungpook Natl Univ Hosp, Daegu, South Korea | Lee, Yun-Soo/AAA-7364-2022; Kim, Young-Bo/AAR-8052-2021; Kim, Soo-Yeon/ADR-9663-2022; Jeon, Minji/HTN-4703-2023 | TISSUE ENGINEERING PART A | TISSUE ENG PT A | 1937-3341 | 1937-335X | 28 | SCIE | CELL & TISSUE ENGINEERING;CELL BIOLOGY;ENGINEERING, BIOMEDICAL;MATERIALS SCIENCE, BIOMATERIALS | 2022 | 4.1 | 42.2 | 0 | PDK4; Bladder cancer; Akt; ERK | English | 2022 | 2022-10-01 | 바로가기 | 바로가기 | |||||||||||||||
| ○ | Meeting Abstract | Topographical regulation for local bone regeneration in type 1 diabetes mellitus: In-vivo | Kim, Min Guk; Eom, Hyeji; Kim, Do-Yeon; Park, Chan Ho | Kyungpook Natl Univ, Sch Dent, Dept Dent Biomat, Sangju, South Korea; Kyungpook Natl Univ, Dept Pharmacol, Sch Dent, Sangju, South Korea | TISSUE ENGINEERING PART A | TISSUE ENG PT A | 1937-3341 | 1937-335X | 28 | SCIE | CELL & TISSUE ENGINEERING;CELL BIOLOGY;ENGINEERING, BIOMEDICAL;MATERIALS SCIENCE, BIOMATERIALS | 2022 | 4.1 | 42.2 | 0 | Diabetes mellitus; Macrophage; Polarization; Osteoimmunomodulation; PCL scaffold; Critical defect; Bone regeneration | English | 2022 | 2022-10-01 | 바로가기 | 바로가기 | ||||||||||||||||
| ○ | ○ | Article | C-reactive protein and statins in heart failure with reduced and preserved ejection fraction | Background: High C-reactive protein (CRP) levels are associated with poor outcomes of heart failure (HF), and statins are known to reduce CRP levels. We investigated the prognostic value of CRP and statin in patients with HF with reduced and preserved ejection fraction (EF). Methods: Altogether, 3,831 patients from the Korean Acute Heart Failure registry were included and stratified according to the tertiles of CRP levels (T1: CRP 1.14 mg/dL). HF with reduced EF (HFrEF), HF with mildly reduced EF (HFmrEF), and HF with preserved EF (HFpEF) were defined as left ventricular ejection fraction (LVEF) = 50%, respectively. The primary endpoints were all-cause, in-hospital, and post-discharge mortality. Results: No significant correlation was observed between CRP levels and LVEF (r = 0.02, P = 0.131). The prevalence of risk factors increased gradually from T1 to T3 in both the types of HF. Overall, 139 (3.6%) and 1,269 (34.4%) patients died during the index admission and follow-up (median: 995 days), respectively. After adjustment, each increase in the CRP tertiles was independently associated with in-hospital mortality (HFrEF: OR 1.58 and 95% CI 1.09-2.30, HFmrEF: OR 1.51 and 95% CI 0.72-3.52, and HFpEF: OR 2.98, 95% CI 1.46-6.73) and post-discharge mortality (HFrEF: HR 1.20, 95% CI 1.08-1.33, HFmrEF: HR 1.38 and 95% CI 1.12-1.70, and HFpEF: HR 1.37, 95% CI 1.02-1.85). In only patients with LVEF > 40% with highest CRP tertile, statin-users showed better survival trend than those without statins. Conclusion: CRP is an excellent prognostic marker for HFrEF, HFmrEF, and HFpEF, implying that the neurohumoral and inflammatory pathways might be independent pathways. Statins may be beneficial in HF patients with increased CRP levels. | Park, Jin Joo; Yoon, Minjae; Cho, Hyoung-Won; Cho, Hyun-Jai; Kim, Kye Hun; Yang, Dong Heon; Yoo, Byung-Su; Kang, Seok-Min; Baek, Sang Hong; Jeon, Eun-Seok; Kim, Jae-Joong; Cho, Myeong-Chan; Chae, Shung Chull; Oh, Byung-Hee; Choi, Dong-Ju | Seoul Natl Univ, Bundang Hosp, Dept Internal Med, Coll Med, Seongnam, South Korea; Yonsei Univ, Dept Internal Med, Coll Med, Seoul, South Korea; Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea; Chonnam Natl Univ, Heart Res Ctr, Gwangju, South Korea; Kyungpook Natl Univ, Coll Med, Dept Internal Med, Daegu, South Korea; Yonsei Univ, Dept Internal Med, Wonju Coll Med, Wonju, South Korea; Catholic Univ Korea, Dept Internal Med, Seoul, South Korea; Sungkyunkwan Univ, Dept Internal Med, Coll Med, Seoul, South Korea; Univ Ulsan, Dept Internal Med, Coll Med, Seoul, South Korea; Chungbuk Natl Univ, Dept Internal Med, Coll Med, Cheongju, South Korea; Kyungpook Natl Univ, Dept Internal Med, Div Cardiol, Chilgok Hosp, Daegu, South Korea; Incheon Sejong Hosp, Cardiovasc Ctr, Div Cardiol, Incheon, South Korea | Jeong, Gi/AAB-2830-2021; choi, jo/O-5940-2014; Oh, Byung-Hee/G-9875-2011; Choi, Dong-Ju/J-5686-2012 | 35799900000; 57201548933; 57222361957; 35285421400; 56150430800; 35277423400; 7102851884; 7405685375; 7201371594; 7004279641; 36065764100; 7401727518; 7101962036; 57216293873; 35274349200 | djchoi@snubh.org; | FRONTIERS IN CARDIOVASCULAR MEDICINE | FRONT CARDIOVASC MED | 2297-055X | 9 | SCIE | CARDIAC & CARDIOVASCULAR SYSTEMS | 2022 | 3.6 | 42.3 | 1.17 | 2025-06-25 | 11 | 11 | heart failure; inflammation; outcomes; C-reactive protein; statin | PROGNOSTIC VALUE; ROSUVASTATIN; ASSOCIATION; MORTALITY; MARKERS; EVENTS; TRIAL; RISK | C-reactive protein; heart failure; inflammation; outcomes; statin | brain natriuretic peptide; C reactive protein; creatinine; dipeptidyl carboxypeptidase inhibitor; hemoglobin; hydroxymethylglutaryl coenzyme A reductase inhibitor; acute coronary syndrome; acute heart failure; aged; anemia; area under the curve; Article; atrial fibrillation; bleeding; blood pressure; body mass; bradycardia; cerebrovascular disease; chronic kidney failure; chronic obstructive lung disease; cohort analysis; controlled study; diabetes mellitus; diagnostic test accuracy study; diastolic blood pressure; echocardiography; estimated glomerular filtration rate; female; heart ejection fraction; heart failure; heart left ventricle ejection fraction; heart rate; heart ventricle tachycardia; human; hypertension; in-hospital mortality; inflammation; ischemic heart disease; kidney failure; leukocyte count; major clinical study; male; physician; receiver operating characteristic; risk factor; sensitivity analysis; smoking; systolic blood pressure; ultrasound; urea nitrogen blood level | English | 2022 | 2022-12-23 | 10.3389/fcvm.2022.1064967 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |||
| ○ | ○ | Correction | Corrigendum: The Prescription Characteristics, Efficacy and Safety of Spironolactone in Real-World Patients With Acute Heart Failure Syndrome: A Prospective Nationwide Cohort Study (vol 9, 791446, 2022) | Na, Soo Jin; Youn, Jong-Chan; Lee, Hye Sun; Jeon, Soyoung; Lee, Hae-Young; Cho, Hyun-Jai; Choi, Jin-Oh; Jeon, Eun-Seok; Lee, Sang Eun; Kim, Min-Seok; Kim, Jae-Joong; Hwang, Kyung-Kuk; Cho, Myeong-Chan; Chae, Shung Chull; Kang, Seok-Min; Choi, Dong-Ju; Yoo, Byung-Su; Kim, Kye Hun; Oh, Byung-Hee; Baek, Sang Hong | Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Crit Care Med, Seoul, South Korea; Catholic Univ, Grad Sch, Dept Med, Seoul, South Korea; Catholic Univ Korea, Catholic Res Inst Intractable Cardiovasc Dis, Seoul St Marys Hosp, Div Cardiol,Dept Internal Med,Coll Med, Seoul, South Korea; Yonsei Univ, Coll Med, Biostat Collaborat Unit, Seoul, South Korea; Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea; Sungkyunkwan Univ, Coll Med, Dept Internal Med, Seoul, South Korea; Univ Ulsan, Coll Med, Asan Med Ctr, Dept Internal Med, Seoul, South Korea; Chungbuk Natl Univ, Coll Med, Dept Internal Med, Cheongju, South Korea; Kyungpook Natl Univ, Coll Med, Dept Internal Med, Daegu, South Korea; Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea; Seoul Natl Univ, Bundang Hosp, Dept Internal Med, Seongnam, South Korea; Yonsei Univ, Wonju Coll Med, Dept Internal Med, Wonju, South Korea; Chonnam Natl Univ, Med Sch, Dept Cardiovasc Med, Gwangju, South Korea; Mediplex Sejong Hosp, Dept Internal Med, Incheon, South Korea | Lee, Hye Sun/J-2154-2015; Lee, Hae/B-1019-2010; Oh, Byung-Hee/G-9875-2011; Choi, Joon/D-6140-2017; Youn, Jong-Chan/AAS-1405-2020; Jeong, Gi/AAB-2830-2021; Lee, Hye/J-2154-2015; Choi, Dong-Ju/J-5686-2012; LEE, JI/L-6920-2013 | 57192305023; 14070921900; 57208650357; 57223622373; 56151235500; 35285421400; 15848011800; 7004279641; 57207065107; 57212315719; 36065764100; 7402426370; 7401727518; 7101962036; 7405685375; 35274349200; 7102851884; 56150430800; 57216293873; 7201371594 | jong.chan.youn@gmail.com;whitesh@catholic.ac.kr; | FRONTIERS IN CARDIOVASCULAR MEDICINE | FRONT CARDIOVASC MED | 2297-055X | 9 | SCIE | CARDIAC & CARDIOVASCULAR SYSTEMS | 2022 | 3.6 | 42.3 | 6.92 | 2025-06-25 | 0 | 3 | acute heart failure syndrome; spironolactone; mineralocorticoid receptor antagonists; drug therapy; outcome | acute heart failure syndrome; drug therapy; mineralocorticoid receptor antagonists; outcome; spironolactone | erratum | English | 2022 | 2022-04-04 | 10.3389/fcvm.2022.888829 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |||||
| ○ | ○ | Article | Long-term use of renin-angiotensin-system inhibitors after acute myocardial infarction is not associated with survival benefits: Analysis of data from the Korean acute myocardial infarction registry-national institutes of health registry | Introduction: Renin-angiotensin-system inhibitors (RASi) have shown survival benefits after acute myocardial infarction (MI), but the role of routine long-term use of RASi remains unclear. Thereby, we explored the therapeutic effects of RASi medication at 1-year follow-up from acute MI. Methods: Using the nationwide Korea Acute Myocardial Infarction Registry-National Institutes of Health (KAMIR-NIH) registry, we included and analyzed 10,822 subjects. Patients were stratified into those taking RASi at 1-year follow-up (n = 7,696) and those not taking RASi at 1-year follow-up (n = 3,126). Patients were followed up for 2-years from the 1-year follow-up; 2-year all-cause mortality and cardiac mortality were analyzed as primary and secondary outcomes, respectively. Results: The use of RASi at 1-year follow-up was not associated with decreased all-cause mortality (log-rank P = 0.195) or cardiac mortality (log-rank P = 0.337). In multivariate analyses, RASi medication at 1-year follow-up did not reduce all-cause mortality (P = 0.758) or cardiac mortality (P = 0.923), while RASi medication at discharge substantially reduced 1-year all-cause and cardiac mortality. Treatment with either an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker at 1-year follow-up did not show survival benefits from 1-year follow-up, respectively. The use of RASi at 1-year follow-up did not show a prognostic interaction between previous history of chronic kidney disease, post-MI acute heart failure, concomitant use of beta-blockers at 1-year follow-up, or 1-year LVEF. Conclusion: Acute MI patients taking RASi at 1-year follow-up were not associated with improved 2-year all-cause mortality or cardiac mortality from the 1-year follow-up. This study provides valuable information regarding tailored medication strategy after acute MI. | Park, Chan Soon; Yang, Han-Mo; Kang, Jeehoon; Han, Jung-Kyu; Park, Kyung Woo; Kang, Hyun-Jae; Koo, Bon-Kwon; Seung, Ki-Bae; Cha, Kwang Soo; Seong, In-Whan; Rha, Seung-Woon; Jeong, Myung Ho; Kim, Hyo-Soo; KAMIR-NIH Registry | Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea; Catholic Univ Korea, Coll Med, Dept Internal Med, Cardiol Div, Seoul, South Korea; Pusan Natl Univ Hosp, Dept Internal Med, Pusan, South Korea; Chungnam Natl Univ, Chungnam Natl Univ Hosp, Coll Med, Dept Internal Med, Daejeon, South Korea; Kyungpook Natl Univ, Coll Med, Dept Internal Med, Daegu, South Korea; Chonnam Natl Univ Hosp, Heart Ctr, Dept Internal Med, Gwangju, South Korea | Han, Jung-Kyu/JGE-4952-2023; Rha, Seung-Woon/AGE-5810-2022; Koo, Bon-Kwon/J-5374-2012; Kang, Hyun-Jae/D-6121-2012; YANG, HANMO/HNB-9532-2023; Park, Kyung Woo/AAX-3046-2020; Kim, Hyo/J-2753-2012 | 57198830480; 55153939700; 55139508800; 55590483500; 35300576900; 27171630200; 35285769200; 7003964208; 7102837700; 35254371300; 8569030400; 56485157500; 33567809200 | hanname@hanmail.net; | FRONTIERS IN CARDIOVASCULAR MEDICINE | FRONT CARDIOVASC MED | 2297-055X | 9 | SCIE | CARDIAC & CARDIOVASCULAR SYSTEMS | 2022 | 3.6 | 42.3 | 0.12 | 2025-06-25 | 1 | 1 | acute myocardial infarction; renin-angiotensin-system inhibitor; angiotensin converting enzyme inhibitor; angiotensin II receptor blocker; mortality; prognosis | CONVERTING-ENZYME-INHIBITOR; LEFT-VENTRICULAR DYSFUNCTION; CARDIOVASCULAR EVENTS; CAPTOPRIL; MORTALITY; MORBIDITY; DISEASE; TRIAL; RISK | acute myocardial infarction; angiotensin converting enzyme inhibitor; angiotensin II receptor blocker; mortality; prognosis; renin-angiotensin-system inhibitor | beta adrenergic receptor blocking agent; acute heart infarction; adult; all cause mortality; Article; cardiovascular mortality; chronic kidney failure; controlled study; echocardiography; female; follow up; heart left ventricle ejection fraction; hospitalization; human; Korea; major clinical study; male; middle aged; mortality; national health organization; outcome assessment; prognosis; renin angiotensin aldosterone system | English | 2022 | 2022-08-31 | 10.3389/fcvm.2022.994419 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |||
| ○ | ○ | Article | The novel bio-SYNTAX scoring system for predicting the prognosis of patients undergoing percutaneous coronary intervention with left main coronary artery disease | BackgroundSimple and effective risk models incorporating biomarkers associated with left main coronary artery (LMCA) stenosis are limited. This study aimed to validate the novel Bio-Clinical SYNTAX score (Bio-CSS) incorporating N-terminal pro-B-type natriuretic peptide (NT-proBNP) in patients with LMCA stenosis. MethodsPatients who underwent percutaneous coronary intervention (PCI) for LMCA stenosis using a drug-eluting stent (n = 275) were included in the study. We developed the Bio-CSS incorporating NT-proBNP and validated the ability of the Bio-CSS to predict major adverse cardiac events (MACEs) and compared its performance to that of the SYNTAX score (SS) and SS II. The MACEs were defined as death, non-fatal myocardial infarction (MI), and repeat revascularizations. ResultsThe Bio-CSS (34.7 +/- 18.3 vs. 51.9 +/- 28.4, p < 0.001), as well as SS (23.6 +/- 7.3 vs. 26.7 +/- 8.1, p = 0.003) and SS II (29.4 +/- 9.9 vs. 36.1 +/- 12.8, p < 0.001), was significantly higher in patients with MACEs. In the Cox proportional hazards model, the log Bio-CSS (hazard ratio 8.31, 95% CI 1.84-37.55) was an independent prognostic factor for MACEs after adjusting for confounding variables. In the receiver operating characteristic curves, the area under the curve of the Bio-CSS was significantly higher compared to those of SS (0.608 vs. 0.706, p = 0.001) and SS II (0.655 vs. 0.706, p = 0.026). Patients were categorized into the three groups based on the tertiles of the Bio-CSS. Patients in the highest tertile of the Bio-CSS had significantly higher MACEs compared to those in the lower two tertiles (log-rank p < 0.001). ConclusionIn patients who underwent PCI for LMCA stenosis, the novel Bio-CSS improved the discrimination accuracy of established combined scores, such as SS and SS II. The addition of NT-proBNP to the clinical and angiographic findings in the Bio-CSS could potentially provide useful long-term prognostic information in these patients. | Yoon, Jae Yong; Lee, Jang Hoon; Kim, Hong Nyun; Kim, Namkyun; Jang, Se Yong; Bae, Myung Hwan; Yang, Dong Heon; Park, Hun Sik; Cho, Yongkeun | CHA Univ, CHA Gumi Med Ctr, Dept Internal Med, Gumi, South Korea; Kyungpook Natl Univ Hosp, Dept Internal Med, Daegu, South Korea; Kyungpook Natl Univ, Sch Med, Daegu, South Korea; Kyungpook Natl Univ, Dept Internal Med, Chilgok Hosp, Daegu, South Korea | Park, Hang-soo/AEH-1640-2022 | 55460558600; 54581258000; 56706769800; 55887032700; 57207977889; 36607356800; 35277423400; 57198844106; 9249593500 | ljhmh75@knu.ac.kr; | FRONTIERS IN CARDIOVASCULAR MEDICINE | FRONT CARDIOVASC MED | 2297-055X | 9 | SCIE | CARDIAC & CARDIOVASCULAR SYSTEMS | 2022 | 3.6 | 42.3 | 0 | 2025-06-25 | 0 | 0 | risk stratification; N-terminal pro-B type natriuretic peptide; left main coronary artery disease; percutaneous coronary intervention; drug eluting stent | BRAIN NATRIURETIC PEPTIDE; LONG-TERM MORTALITY; RISK STRATIFICATION; BYPASS-SURGERY; ELUTING STENTS; HEART-FAILURE; OUTCOMES; VALIDATION; STENOSIS; DYSPNEA | drug eluting stent; left main coronary artery disease; N-terminal pro-B type natriuretic peptide; percutaneous coronary intervention; risk stratification | acetylsalicylic acid; adenosine triphosphate; amino terminal pro brain natriuretic peptide; angiotensinogen; beta adrenergic receptor blocking agent; biolimus eluting coronary stent; biological marker; clopidogrel; creatinine; diuretic agent; drug eluting coronary stent; drug eluting stent; everolimus eluting coronary stent; heparin; hydroxymethylglutaryl coenzyme A reductase inhibitor; paclitaxel eluting coronary stent; sirolimus eluting coronary stent; ticagrelor; zotarolimus eluting coronary stent; acute coronary syndrome; adult; aged; angiography; ankle brachial index; area under the curve; Article; blood clotting time; cardiogenic shock; cardiovascular risk; confounding variable; controlled study; coronary angiography; coronary artery bypass graft; coronary artery disease; coronary artery obstruction; diabetes mellitus; diagnostic accuracy; diagnostic test accuracy study; dual antiplatelet therapy; echocardiography; electrocardiography; electrochemiluminescence; estimated glomerular filtration rate; female; follow up; heart arrest; heart infarction; heart left ventricle ejection fraction; heart muscle ischemia; hemodialysis; hospitalization; human; hyperlipidemia; hypertension; intravascular ultrasound; left anterior descending coronary artery; left coronary artery; loading drug dose; major adverse cardiac event; major clinical study; male; non ST segment elevation myocardial infarction; observational study; percutaneous coronary intervention; peripheral occlusive artery disease; prognosis; receiver operating characteristic; revascularization; scoring system; sinus rhythm; ST segment elevation myocardial infarction; stenosis; SYNTAX score; target lesion revascularization; transluminal coronary angioplasty | English | 2022 | 2022-09-23 | 10.3389/fcvm.2022.912286 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |||
| ○ | ○ | Article | The Prescription Characteristics, Efficacy and Safety of Spironolactone in Real-World Patients With Acute Heart Failure Syndrome: A Prospective Nationwide Cohort Study | BackgroundRandomized clinical trials of spironolactone showed significant mortality reduction in patients with heart failure with reduced ejection fraction. However, its role in acute heart failure syndrome (AHFS) is largely unknown. AimTo investigate the prescription characteristics, efficacy and safety of spironolactone in real-world patients with AHFS. Methods5,136 AHFS patients who survived to hospital discharge using a nationwide prospective registry in Korea were analyzed. The primary efficacy outcome was 3-year all-cause mortality. ResultsSpironolactone was prescribed in 2,402 (46.8%) at discharge: = 25 mg, and = 50 mg in 358 patients (14.9%). Patients treated with spironolactone had a lower proportion of chronic renal failure and renal replacement therapy during hospitalization and had lower serum creatinine level than those who did not. In overall patients, 3-year mortality was not different in both groups (35.9 vs. 34.5%, P = 0.279). The incidence of renal injury and hyperkalemia was 2.2% and 4.3%, respectively, at the first follow-up visit. The treatment effect of spironolactone on mortality was different across subpopulations according to LVEF. The use of spironolactone was associated with a significant reduction in 3-year morality in patients with LVEF 26%. ConclusionsAlthough spironolactone was frequently used at lower doses in real-world practice, use of spironolactone significantly reduced 3-year mortality in patients with severely reduced LVEF with acceptable safety profile. However, our findings remain prone to various biases and further prospective randomized controlled studies are needed to confirm these findings. | Na, Soo Jin; Youn, Jong-Chan; Lee, Hye Sun; Jeon, Soyoung; Lee, Hae-Young; Cho, Hyun-Jai; Choi, Jin-Oh; Jeon, Eun-Seok; Lee, Sang Eun; Kim, Min-Seok; Kim, Jae-Joong; Hwang, Kyung-Kuk; Cho, Myeong-Chan; Chae, Shung Chull; Kang, Seok-Min; Choi, Dong-Ju; Yoo, Byung-Su; Kim, Kye Hoon; Oh, Byung-Hee; Baek, Sang Hong | Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Dept Crit Care Med, Seoul, South Korea; Catholic Univ, Grad Sch, Dept Med, Seoul, South Korea; Catholic Univ Korea, Seoul St Marys Hosp, Catholic Res Inst Intractable Cardiovasc Dis, Coll Med,Div Cardiol,Dept Internal Med, Seoul, South Korea; Yonsei Univ, Coll Med, Biostat Collaborat Unit, Seoul, South Korea; Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea; Sungkyunkwan Univ, Coll Med, Dept Internal Med, Seoul, South Korea; Univ Ulsan, Coll Med, Asan Med Ctr, Dept Internal Med, Seoul, South Korea; Chungbuk Natl Univ, Coll Med, Dept Internal Med, Cheongju, South Korea; Kyungpook Natl Univ, Coll Med, Dept Internal Med, Daegu, South Korea; Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea; Seoul Natl Univ, Bundang Hosp, Dept Internal Med, Seongnam, South Korea; Yonsei Univ, Wonju Coll Med, Dept Internal Med, Wonju, South Korea; Chonnam Natl Univ, Med Sch, Dept Cardiovasc Med, Gwangju, South Korea; Mediplex Sejong Hosp, Dept Internal Med, Incheon, South Korea | ; Youn, Jong-Chan/AAS-1405-2020; Choi, Dong-Ju/J-5686-2012; Lee, Hye/J-2154-2015; Lee, Hye Sun/J-2154-2015; Jeong, Gi/AAB-2830-2021; Oh, Byung-Hee/G-9875-2011; LEE, JI/L-6920-2013; Lee, Hae/B-1019-2010; Choi, Joon/D-6140-2017 | 57192305023; 14070921900; 57208650357; 57223622373; 56151235500; 35285421400; 15848011800; 7004279641; 57207065107; 57212315719; 36065764100; 7402426370; 7401727518; 7101962036; 7405685375; 35274349200; 7102851884; 56150430800; 57216293873; 7201371594 | jong.chan.youn@gmail.com;whitesh@catholic.ac.kr; | FRONTIERS IN CARDIOVASCULAR MEDICINE | FRONT CARDIOVASC MED | 2297-055X | 9 | SCIE | CARDIAC & CARDIOVASCULAR SYSTEMS | 2022 | 3.6 | 42.3 | 0.35 | 2025-06-25 | 5 | 3 | acute heart failure syndrome; spironolactone; mineralocorticoid receptor antagonists; drug therapy; outcome | LONG-TERM; OUTCOMES; ASSOCIATION; MORTALITY; REGISTRY; SOCIETY; MARKERS | acute heart failure syndrome; drug therapy; mineralocorticoid receptor antagonists; outcome; spironolactone | amino terminal pro brain natriuretic peptide; brain natriuretic peptide; C reactive protein; spironolactone; acute heart failure; adult; aged; all cause mortality; Article; clinical article; clinical outcome; cohort analysis; controlled study; dose response; drug efficacy; drug safety; echocardiography; female; follow up; glomerulus filtration rate; gynecomastia; heart left ventricle ejection fraction; human; hyperkalemia; hypotension; incidence; kidney injury; Korea; major clinical study; male; middle aged; multicenter study; prescription; prospective study; Risk, Injury, Failure, Loss of kidney function and End-stage kidney disease classification; sensitivity analysis | English | 2022 | 2022-02-22 | 10.3389/fcvm.2022.791446 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |||
| ○ | ○ | Article | Association between Timing and Duration of Adjuvant Chemotherapy and Colorectal Cancer Survival in Korea, 2011-2014: A Nationwide Study based on the Health Insurance Review and Assessment Service Database | Background: Population-based analyses of the treatment outcomes of colorectal cancer (CRC) in Asian countries are limited. Therefore, we conducted a nationwide study to assess the relationship between the timing and duration of adjuvant chemotherapy (AC) and survival in patients with CRC in South Korea. Methods: Data on AC from the Health Insurance Review and Assessment Service Database (HIRA) were analyzed, and the survival of patients who underwent curative-intent surgical resection for CRC between 2011 and 2014 was investigated. Results: From the HIRA data, 45,992 patients with stage II-III CRC were identified. Chemotherapy regimens were administered as follows: 10,640 (23.3%) received 5-fluorouracil and leucovorin/capecitabine (FL/CAP), 13,083 (28.7%) received FUCAP plus oxaliplatin (FOLFOX/CAPDX), 299 (0.7%) received uracil and tegafur/doxifluridine (UFT/D), and 21,570 (47.3%) underwent surgery alone. Patients who did not receive AC had worse survival than those who received AC in both the colon and rectum groups (HR, 1.96, 95% CI, 1.85-2.07 and HR, 2.18, 95% CI, 2.01-2.37, respectively). Regarding patients with stage II-III CRC, AC initiation >= 2 months after surgery was associated with a significant decrease in overall survival (OS) (FUCAP: HR, 1.82; 95% CI, 1.53-2.17 and FOLFOX/CAPDX: HR, 2.92; 95% CI, 2.47-3.45); however, the effects of UFT/D regimens were not statistically significant. For patients with stage II-III colon cancer, AC 3 months can potentially have an OS benefit in patients with stage II-III CRC. | Choi, Jin Hwa; Lee, Ji Sung; Baek, Sun Kyung; Kim, Jong Gwang; Kim, Tae Won; Sohn, Seung Kook; Kang, Mi Yeon; Lee, Sang-Cheol; Hwang, In Gyu | Chung Ang Univ Hosp, Dept Radiat Oncol, Seoul, South Korea; Asan Med Ctr, Clin Res Ctr, Seoul, South Korea; Kyung Hee Univ Med Ctr, Seoul, South Korea; Kyungpook Natl Univ, Dept Oncol Hematol, Med Ctr, Daegu, South Korea; Asan Med Ctr, Dept Oncol, Seoul, South Korea; Hlth Insurance Review & Assessment Serv, Wonju, South Korea; Hlth Insurance Review & Assessment Serv, Qual Assessment Management Div, Wonju, South Korea; Soonchunhyang Univ, Cheonan Hosp, Cheonan, South Korea; Chung Ang Univ, Dept Internal Med, Coll Med, 224-1 Heukseok Dong, Seoul 06973, South Korea | Kim, Tae Won/GRX-7323-2022; CHOI, JIN HWA/LWZ-8057-2024 | 57213021227; 57212925539; 36631425100; 59501049300; 56504151300; 57214581136; 57212602700; 56596320900; 7201614898 | leptin72@gmail.com;oncology@cau.ac.kr; | JOURNAL OF CANCER | J CANCER | 1837-9664 | 13 | 7 | SCIE | ONCOLOGY | 2022 | 3.9 | 42.5 | 0.3 | 2025-06-25 | 3 | 3 | colorectal cancer; adjuvant chemotherapy; timing; duration | III COLON-CANCER; STAGE-II; FLUOROURACIL; LEUCOVORIN; THERAPY; OXALIPLATIN; INITIATION; SURGERY | adjuvant chemotherapy; colorectal cancer; duration; timing | antineoplastic agent; capecitabine; capecitabine plus folinic acid; doxifluridine; doxifluridine plus tegafur; fluorouracil; folinic acid; oxaliplatin; tegafur; unclassified drug; uracil; adjuvant chemotherapy; adult; aged; Article; cancer staging; cancer surgery; cancer survival; cohort analysis; colorectal cancer; controlled study; data base; disease association; female; health insurance; health insurance review and assessment service database; human; Korea; major clinical study; male; multicenter study; observational study; postoperative period; retrospective study; treatment duration; treatment outcome | English | 2022 | 2022 | 10.7150/jca.71141 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | ○ | Article | Exonuclease 1 genetic variant is associated with clinical outcomes of pemetrexed chemotherapy in lung adenocarcinoma | Pemetrexed is an anti-folate agent which is one of the most frequently used chemotherapy agents for non-squamous non-small cell lung cancer (NSCLC) patients. However, clinical response to pemetrexed chemotherapy and survival outcome of patients varies significantly. We evaluated whether the genetic variants in miRNA target sites may affect the treatment outcome of pemetrexed chemotherapy in lung adenocarcinoma patients. One hundred SNPs in miRNA binding regions in cancer-related genes were obtained from the crosslinking, ligation, and sequencing of hybrids (CLASH) and CancerGenes database, and the associations with the response to pemetrexed chemotherapy and survival outcomes were investigated in 314 lung adenocarcinoma patients. Two polymorphisms, EXO1 rs1047840G>A and CAMKK2 rs1653586G>T, were significantly associated with worse chemotherapy response (adjusted odds ratio [aOR] = 0.41, 95% CI = 0.24-0.68, P = 0.001, under dominant model; and aOR = 0.33, 95% CI = 0.16-0.67, P = 0.002, under dominant model, respectively) and worse OS (adjusted hazard ratio [aHR] = 1.34, 95% CI = 1.01-1.77, P = 0.04, under dominant model; and aHR = 1.50, 95% CI = 1.06-2.13, P = 0.02, under dominant model, respectively) in multivariate analyses. Significantly increased luciferase activity was noted in EXO1 rs1047840 A allele compared to G allele. In conclusion, two SNPs in miRNA binding sites, especially EXO1 rs1047840G>A, were associated with the chemotherapy response and survival outcome in lung adenocarcinoma patients treated with pemetrexed. | Hong, Mi Jeong; Park, Ji Eun; Lee, Shin Yup; Lee, Jang Hyuck; Choi, Jin Eun; Kang, Hyo-Gyoung; Do, Sook Kyung; Jeong, Ji Yun; Shin, Kyung Min; Lee, Won Ki; Seok, Yangki; Choi, Sun Ha; Lee, Yong Hoon; Seo, Hyewon; Yoo, Seung Soo; Lee, Jaehee; Cha, Seung Ick; Kim, Chang Ho; Park, Jae Yong | Kyungpook Natl Univ, Sch Med, Dept Biochem, Daegu, South Korea; Kyungpook Natl Univ, Cell & Matrix Res Inst, Sch Med, Daegu, South Korea; Kyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea; Kyungpook Natl Univ, Dept Biomed Sci, BK21 Plus KNU Biomed Convergence Program, Daegu, South Korea; Kyungpook Natl Univ, Sch Med, Dept Pathol, Daegu, South Korea; Kyungpook Natl Univ, Dept Radiol, Sch Med, Daegu, South Korea; Kyungpook Natl Univ, Med Res Collaborat Ctr, Kyungpook Natl Univ Hosp, Daegu, South Korea; Kyungpook Natl Univ, Sch Med, Daegu, South Korea; Soonchunhyang Univ, Dept Thorac Surg, Gumi Hosp, Gumi, South Korea; Kyungpook Natl Univ, Chilgok Hosp, Lung Canc Ctr, 807 Hoguk Ro, Daegu 41404, South Korea | Lee, Jaehee/S-1697-2018; Lee, Sang-Hwa/ISU-5166-2023; Choi, Sun Ha/HPD-7234-2023; JY, LEE/GRS-9767-2022; Lee, Yoojin/AAB-9799-2022 | 55613917100; 57195437358; 49863712700; 57161223200; 37107028100; 8573181300; 56333658000; 57205472984; 7402410737; 57222170628; 37052883000; 57199723585; 57199022948; 55612130200; 56479781600; 13805476000; 35227126400; 7409873555; 58360293800 | shinyup@knu.ac.kr;jaeyong@knu.ac.kr; | JOURNAL OF CANCER | J CANCER | 1837-9664 | 13 | 15 | SCIE | ONCOLOGY | 2022 | 3.9 | 42.5 | 0.2 | 2025-06-25 | 2 | 2 | lung adenocarcinoma; miRNA target sites; genetic variants; chemotherapy; response; survival | EXO1 GENE; CANCER; POLYMORPHISMS; RISK; SUSCEPTIBILITY; RECOMBINATION; SENSITIVITY; POPULATION; MICRORNAS; PLATINUM | chemotherapy; genetic variants; lung adenocarcinoma; miRNA target sites; response; survival | cisplatin; exonuclease; exonuclease 1; firefly luciferase; genomic DNA; luciferase; microRNA; microRNA 185; microRNA 30e; pemetrexed; Renilla luciferin 2 monooxygenase; unclassified drug; adult; aged; Article; CAMKK2 gene; cancer combination chemotherapy; cancer survival; clinical outcome; controlled study; cross linking; female; follow up; gene; gene frequency; gene linkage disequilibrium; genetic association; genetic variability; genotyping; human; lung adenocarcinoma; major clinical study; male; multiple cycle treatment; NCI-H1299 cell line; overall survival; people by smoking status; response evaluation criteria in solid tumors; single nucleotide polymorphism; treatment outcome | English | 2022 | 2022 | 10.7150/jca.78498 | 바로가기 | 바로가기 | 바로가기 | 바로가기 |
페이지 이동: